NILCO signaling is a novel biomarker in thyroid cancer

• Published in: The FASEB journal 2020-04, Vol.34 (S1), p.1-1
• Main Authors: Erkasap, Nilufer, Badak, Bartu, Ozyurt, Rumeysa, Ozkurt, Mete, Guzel, Derya, Erkasap, Serdar, Ihtiyar, Enver, Dundar, Emine, Arik, Deniz
• Format: Article
• Language: English
• ISSN: 0892-6638; 1530-6860
• DOI: 10.1096/fasebj.2020.34.s1.09252

Abstract only The pathways and therapeutic targets play a role in potential molecular mechanisms of thyroid cancer therapy have been studied in recent years. One of these pathways is Notch signaling. Recent studies on cancer have been reported to be Notch regulators of leptin and IL‐1. In addition, a new signaling crosstalk between Notch, interleukin‐1 (IL‐1) and leptin [Notch, IL‐1 and leptin crosstalk outcome (NILCO)] is important in proliferation, migration and angiogenesis. However, it is not clear whether activation of this signaling crosstalk is related to thyroid cancer and diverse clinicopathological factors. The aim of this study was to demonstrate the expression changes of Notch1, Leptin, Leptin receptor ObRb, IL‐1α, IL‐1β, IL1R axis in human thyroid cancer tissues. Notch1, Leptin, ObRb, IL‐1α, IL‐1β, IL1R mRNA expressions were analyzed by real‐time PCR in human tissue of normal and thyroid tumors from 27 patients. In this study, we show that leptin, IL‐1α, IL1R are over‐expressed in human thyroid carcinoma tissues compared with normal thyroid tissues. In addition to, mean plasma leptin, T3 and T4 concentration was significantly higher in thyroid cancer patients compared with healthy people. These results indicate that NILCO could be critical in the development of thyroid cancer and this is a useful clinical biomarker in thyroid carcinoma. The present study was approved by the Ethics Committee of Eskisehir Osmangazi University for Clinical Research (80558721/66) and was performed in accordance with the ethical standards of Helsinki Declaration.